Windtree Therapeutics, Inc. (NASDAQ: WINT)

1. Introduction

Windtree Therapeutics, Inc., founded in 1992 and headquartered in Warrington, Pennsylvania, is a clinical-stage biopharmaceutical and medical device company. It develops novel therapies for acute cardiovascular and pulmonary conditions, targeting markets with significant unmet medical needs.

2. Corporate Structure

• Employees: 11–50
• Headquarters: Warrington, PA
• Management Team:
  • Jed Andrew Latkin, President & CEO (appointed December 1, 2024)
  • Eric Curtis, President & COO (joined March 2020)
  • Steve Simonson, M.D., SVP & Chief Medical Officer
  • Jamie McAndrew, SVP & Chief Financial Officer (appointed September 2024)
  • George Cox, VP of Technical Operations (appointed April 2008)

3. Recent Developments and News

• February 18, 2025: The Board approved a 1-for-50 reverse stock split, effective February 20, 2025. Common shares will trade on a split-adjusted basis under the ticker WINT.
• May 16, 2025: Filed a preliminary Form S-1 with the SEC for potential securities registration under the Securities Act of 1933.
• May 2025: Entered into a binding agreement to acquire Titan Environmental Services, Inc., which operates in the waste management sector, potentially supporting revenue diversification.
• June 2025: Presented istaroxime and selective SERCA2a activator data at the European Society of Cardiology Heart Failure Conference in Belgrade, Serbia.
• July 2025 (planned): Interim analysis results are expected for the SEISMiC SCAI Stage C Phase 2 study of istaroxime.
• Undated: Announced a policy to accept digital currencies as payment and hold certain cryptocurrencies as assets.

4. Financial and Strategic Analysis

4.1 Stock Performance (as of 2025-06-10)

Metric	Value
Share Price	$0.9998
Daily Change	+79.47%
Volume	18,290,828
Exchange	NASDAQ
Ticker	WINT

4.2 Financial Position (Q1 2025)

• Cash and Equivalents: $1.17 M
• Total Debt/Equity: 15.34%
• Trailing 12-Month Net Loss: $20.75 M
• Levered Free Cash Flow (TTM): -$13.41 M

4.3 Capital and Corporate Actions

• Reverse Stock Split: Executed to satisfy the $1.00 minimum bid requirement for continued Nasdaq listing.
• Equity Offering Preparation: The preliminary S-1 filing suggests plans for additional capital raising.

4.4 Strategic Initiatives

• Pipeline Advancement: Istaroxime is in Phase 2 for acute heart failure; preclinical programs include SERCA2a activators and aPKCi inhibitors targeting oncology.
• Diversification: The acquisition of Titan Environmental Services aims to enhance revenue from non-biotech sectors.
• Payment Innovation: Plans to incorporate cryptocurrency as a method of payment may provide alternative funding and transaction channels.

5. Market Position and Industry Context

• Sector: Pharmaceutical Manufacturing, Biotechnology
• Core Markets: Acute heart failure, cardiovascular critical care, oncology, pulmonary therapies
• Competitive Landscape: Competes with established pharmaceutical and biotech firms focused on heart failure and oncology treatments.
• Volatility and Beta: 9.34% volatility; a beta of 0.76 indicates lower correlation with broader market movements.
• Analyst 1-Year Target: $4.00 per share

6. TL;DR

• Executed a 1-for-50 reverse stock split on February 20, 2025, to meet Nasdaq bid-price rules.
• Filed a preliminary S-1 on May 16, 2025, indicating an upcoming equity raise.
• Targeted July 2025 for interim data from the Phase 2 SEISMiC study of istaroxime; supporting data were presented in June 2025 at the ESC Heart Failure Conference.
• Agreed to acquire Titan Environmental Services for revenue diversification and announced a new cryptocurrency acceptance policy.
• Shares traded at $0.9998 (+79.47%) on June 10, 2025; the market capitalization is in the low single-digit millions, supported by asset development in heart failure and oncology treatments.